Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 340
- Registration Number
- NCT01215643
- Locations
- 🇺🇸
The North Texas Research Institute, Arlington, Texas, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Liver Associates of Texas, Houston, Texas, United States
A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01194037
Ph IIA Study (SOC +/- NS5B)
- Conditions
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT01193361
- Locations
- 🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 459
- Registration Number
- NCT01183169
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
- Conditions
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01180790
- Locations
- 🇧🇪
Clinical Trial Site, Gent, Oost-Vlaanderen, Belgium
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT01170962
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Liver Associates Of Texas, Houston, Texas, United States
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 205
- Registration Number
- NCT01143662
- Locations
- 🇨🇳
Tianjin Third Central Hospital, Tianjin, China
🇨🇳First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
🇨🇳Tangdu Hospital, Fourth Military Medical University, Xian, China
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT01140997
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Xiangya Second Hospital, Central-south University, Changsha, China
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 558
- Registration Number
- NCT01125189
- Locations
- 🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸Cli, Los Angeles, California, United States
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT01072695
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.